| Literature DB >> 25789994 |
Eelco Franz1, Angela H A M van Hoek1, Mark Wuite1, Fimme J van der Wal2, Albert G de Boer2, E I Bouw1, Henk J M Aarts1.
Abstract
The complexity regarding Shiga toxin-producing Escherichia coli (STEC) in food safety enforcement as well as clinical care primarily relates to the current inability of an accurate risk assessment of individual strains due to the large variety in serotype and genetic content associated with (severe) disease. In order to classify the clinical and/or epidemic potential of a STEC isolate at an early stage it is crucial to identify virulence characteristics of putative pathogens from genomic information, which is referred to as 'predictive hazard identification'. This study aimed at identifying associations between virulence factors, phylogenetic groups, isolation sources and seropathotypes. Most non-O157 STEC in the Netherlands belong to phylogroup B1 and are characterized by the presence of ehxA, iha and stx2, but absence of eae. The large variability in the number of virulence factors present among serogroups and seropathotypes demonstrated that this was merely indicative for the virulence potential. While all the virulence gene associations have been worked out, it appeared that there is no specific pattern that would unambiguously enable hazard identification for an STEC strain. However, the strong correlations between virulence factors indicate that these arrays are not a random collection but are rather specific sets. Especially the presence of eae was strongly correlated to the presence of many of the other virulence genes, including all non-LEE encoded effectors. Different stx-subtypes were associated with different virulence profiles. The factors ehxA and ureC were significantly associated with HUS-associated strains (HAS) and not correlated to the presence of eae. This indicates their candidacy as important pathogenicity markers next to eae and stx2a.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25789994 PMCID: PMC4366395 DOI: 10.1371/journal.pone.0120353
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Primers and probes used for gene-content analysis in non-O157 STEC.
| Target | Genetic support | Encoded protein or family effector | Primer sequences (5’-3’) | Annealing temperature (°C) | Productsize (bp) | Reference |
|---|---|---|---|---|---|---|
|
| O-Island 57 | Adhesin | Forward: TGGTGGCCCGCATACAGCReverse: TGCCCAGTCAGCCCAGGTTA | 58 | 501 | [ |
|
| Plasmid and chromosome | Heat-stable enterotoxin EAST1 | Forward: CCATCAACACAGTATATCCGAReverse: GGTCGCGAGTGACGGCTTTGT | 60 | 111 | [ |
|
| Chromosome | Heme/hemoglobin receptor | Forward: GACGAACCAACGGTCAGGATReverse: TGCCGCCAGTACCAAAGACA | 60 | 279 | [ |
|
| O-Island 57 | Putative killer protein | Forward: ATGCTCGTCACATATAGATTGReverse: GTTCGTAAGCTGTGAAGACA | 58 | 201 | [ |
|
| LEE | Intimin adhesin | Forward: CATTGATCAGGATTTTTCTGGTGATAReverse: CTCATGCGGAAATAGCCGTTAProbe: FAM-ATAGTCTCGCCAGTATTCGCCACCAATACC-BHQ1 | 60 | 102 | [ |
|
| O-Island 122 | EHEC factor for adherence | Forward: CTCCCAGAGATAATTTTGAGGReverse: CAACTGTATGCGAATAGTACTC | 60 | 504 | [ |
|
| pO157 | Enterohemolysin | Forward: ATCATGTTTTCCGCCAATGReverse: ATCATGTTTTCCGCCAATGProbe: FAM-CGTGATTTTGAATTCAGAACCGGTGG-BHQ1 | 55 | 126 | [ |
|
| O-Island 122 | Microcolony formation and F-actin aggregation | Forward: GAATAACAATCACTCCTCACCReverse: TTACAGTGCCCGATTACG | 55 | 233 | [ |
|
| pO157 | Type-II effector | Forward: TCGTCAGGAGGATGTTCAGReverse: CGACTGCACCTGTTCCTGATTA | 58 | 1,063 | [ |
|
| O-Island 43 & O-Island 48 | Iron regulated adhesin | Forward: TGTATGGCTCTGATGCGATG | 60 | 1,218 | [ |
| Reverse: AGGTGTAATTCAGTGACAGCG | This study | |||||
|
| O-Island 43 & O-Island 48 | Iron regulated adhesin | Forward: TGTATGGCTCTGATGCGATGReverse: GTCCAGGCATCGGTCACG | 60 | 867 | [ |
|
| O-Island 71 | Disruption tight junctions and protein trafficking | Forward: ATGAACATTCAACCGACCATACReverse: GACTCTTGTTTCTTGGATTATATCAAA | 55 | 1,296 | [ |
|
| O-Island 122 | Immunomodulation | Forward: GGAAGTTTGTTTACAGAGACG Reverse: AAAATGCCGCTTGATACC | 55 | 297 | [ |
|
| O-Island 36 | Non-LEE encoded type III effector | Forward: GTTAATACTAAGCAGCATCCReverse: CCATATCAAGATAGATACACC | 52 | 475 | [ |
|
| O-Island 36 | Immunomodulation, zinc-metalloprotease | Forward: ACAGTCCAACTTCAACTTTTCCReverse: ATCGTACCCAGCCTTTCG | 55 | 777 | [ |
|
| O-Island 36 | Immunomodulation, zinc-metalloprotease | Forward: GGTATTACATCAGTCATCAAGGReverse: TTGTGGAAAACATGGAGC | 55 | 426 | [ |
|
| O-Island 122 | Immunomodulation | Forward: GTATAACCAGAGGAGTAGCReverse: GATCTTACAACAAATGTCC | 52 | 260 | [ |
|
| O-Island 71 | Disruption protein trafficking | Forward: ATGTTACCAACAAGTGGTTCTTCReverse: ATCCACATTGTAAAGATCCTTTGTT | 55 | 567 | [ |
|
| O-Island 71 | Ubiquitin ligase | Forward: ATGTTATCGCCCTCTTCTATAAATReverse: ACTTAATACTACACTAATAAGATCCA | 55 | 902 | [ |
|
| O-Island 71 | Ubiquitin ligase | Forward: ACCAGAAACCTGACTTCGReverse: CAGCATCTTCATATACTACAGC | 55 | 406 | [ |
|
| O-Island 57 | Ubiquitin ligase | Forward: GGATGGAACCATACCTGGReverse: CGCAATCAATTGCTAATGC | 56 | 551 | [ |
|
| O-Island 57 | Ubiquitin ligase | Forward: TGGAGGCTTTACGTCATGTCGReverse: CCGGAACAAAGGGTTCACG | 55 | 504 | [ |
|
| O-Island 57 | Ubiquitin ligase | Forward: CGGGTCAGTGGATGATATGAGCReverse: AAGTAGCATCTAGCGGTCGAGG | 55 | 424 | [ |
|
| O-Island 71 | Ubiquitin ligase | Forward: GTTCGTGCCCGAATTGTAGCReverse: CACCAACCAAACGAGAAAATG | 55 | 409 | [ |
|
| O-Island 36 | Immunomodulation | Forward: GTTACCACCTTAAGTATCCReverse: GTTTCTCATGAACACTCC | 55 | 456 | [ |
|
| O-Island 71 | Immunomodulation | Forward: AACGCCTTATATTTTACCReverse: AGCACAATTATCTCTTCC | 52 | 589 | [ |
|
| Chromosome | RNA polymerase, sigma S | Forward: CTTGCATTTTGAAATTCGTTACReverse: GATGATGAACACATAGGATGCReverse: GCCAGCCTCGCTTGAGACSequencing: CCTTATGAGTCAGAATACGCSequencing: CTCTGCTTCATATCGTCATC | 56 | 1,2581,163 | [ |
|
| pO113 | STEC autoagglunating adhesin | Forward: CGTGATGAACAGGCTATTGCReverse: ATGGACATGCCTGTGGCAAC | 60 | 119 | [ |
|
| Chromosome | Shiga toxin | Forward: TTTGTYACTGTSACAGCWGAAGCYTTACGReverse: CCCCAGTTCARWGTRAGRTCMACRTCProbe: FAM-CTGGATGATCTCAGTGGGCGTTCTTATGTAA-BHQ1 | 60 | 131 | [ |
|
| Chromosome | Shiga toxin | Forward: TTTGTYACTGTSACAGCWGAAGCYTTACGReverse: CCCCAGTTCARWGTRAGRTCMACRTCProbe: FAM-TCGTCAGGCACTGTCTGAAACTGCTCC-BHQ1 | 60 | 128 | [ |
|
| Chromosome | Shiga toxin | Forward: GATACTGRGBACTGTGGCCReverse: CCGKCAACCTTCACTGTAAATGTGReverse: GCCACCTTCACTGTGAATGTG | 65 | 349347 | [ |
|
| Chromosome | Shiga toxin | Forward: AAATATGAAGAAGATATTTGTAGReverse: CAGCAAATCCTGAACCTGACG | 65 | 251 | [ |
|
| Chromosome | Shiga toxin | Forward: GAAAGTCACAGTTTTTATATACAACGReverse: CCGGCCACYTTTACTGTGAATGTA | 65 | 177 | [ |
|
| Chromosome | Shiga toxin | Forward: AAARTCACAGTCTTTATATACAACGGGReverse: TTYCCGGCCACTTTTACTGTG | 65 | 179 | [ |
|
| Chromosome | Shiga toxin | Forward: AAARTCACAGTCTTTATATACAACGGGReverse: GCCTGATGCACAGGTACTGGAC | 65 | 280 | [ |
|
| Chromosome | Shiga toxin | Forward: CGGAGTATCGGGGAGAGGCReverse: CTTCCTGACACCTTCACAGTAAA | 65 | 411 | [ |
|
| Chromosome | Shiga toxin | Forward: TGGGCGTCATTCACTGGTTGReverse: TAATGGCCGCCCTGTCTCC | 65 | 424 | [ |
|
| Chromosome | Shiga toxin | Forward: CACCGGGTAGTTATATTTCTGTGGATReverse: GATGGCAATTCAGAATAACCGCT | 65 | 573 | [ |
|
| pO113 | Subtilase cytotoxin | Forward: TATGGCTTCCCTCATTGCReverse: TATAGCTGTTGCTTCTGACG | 54 | 556 | [ |
|
| OI-43 & OI-48 | Tellurite resistance cluster | Forward: GCCAGGTTGGCCGTTTCReverse: CCGTCACTCGATACGGCAATProbe: FAM-AAAACAAAAAATTCATGCAGGGCACCG-BHQ1 | 55 | 82 | [ |
|
| pO157 | Homolog of | Forward: CAACAGCCCCTTCATTCCATTCReverse: TTGCCACATTGCTAAGATAACG | 58 | 555 | This study |
| TspE4.C2 | chromosome | Esterase-lipase protein | Forward: GAGTAATGTCGGGGCATTCAReverse: CGCGCCAACAAAGTATTACG | 60 | 152 | [ |
|
| OI-43 & OI-48 | Urease-associated protein | Forward: TCTAACGCCACAACCTGTACReverse: GAGGAAGGCAGAATATTGGG | 60 | 397 | [ |
|
| chromosome | Unknown | Forward: TGAAGTGTCAGGAGACGCTGReverse: ATGGAGAATGCGTTCCTCAAC | 60 | 211 | [ |
Note:
a These targets were used in a multiplex format in the phylogenetic group PCR.
Fig 1Prevalence of virulence genes among all STEC included in this study (blue bars, n = 209), the top 4 most important non-O157 serogroups (O26, O103, O111 and O145) in the European Union present in our dataset (red bars, n = 20), and the top 4 most important non-O157 serogroups (excluding the top 4 EU serogroups; O63, O91, O113 and O146) in the Netherlands present in our dataset (green bars, n = 45).
Fig 2Distribution of Shiga toxin subtypes among all STEC isolates included in this study (blue bars, n = 209), the top 4 most important non-O157 serogroups (O26, O103, O111 and O145) in the European Union present in our dataset (red bars, n = 20), and the top 4 most important non-O157 serogroups (excluding the top 4 EU serogroups; O63, O91, O113 and O146) in the Netherlands present in our dataset (green bars, n = 45.
Fig 3Boxplots of the number of virulence markers present in isolates with different stx-subtypes.
Solid horizontal line represents the median, the box represents the 25%-75% quartile range, the stems represent the minimum and maximum values, asterisks represent outliers.
Significant (Chi-square P<0.05) positive and negative associated virulence markers with different stx-subtypes.
|
| Positive associated virulence genes | Negative associated virulence genes |
|---|---|---|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
Phylogenetic distribution of virulence genes.
| Phylogroup/Virulence gene | An = 42 | B1n = 132 | B2n = 16 | Dn = 19 | P-value | ORA+B1 vs. B2+D |
|---|---|---|---|---|---|---|
|
| 7% | 10% | 44% | 26% | 0.003 | 0.19 |
|
| 24% | 15% | 50% | 26% | 0.006 | 0.29 |
|
| 43% | 65% | 6% | 37% | <0.001 | 3.33 |
|
| 38% | 77% | 31% | 42% | <0.001 | 3.33 |
|
| 14% | 5% | 25% | 26% | 0.004 | 0.20 |
|
| 12% | 0% | 19% | 5% | 0.002 | n.s. |
|
| 19% | 2% | 19% | 5% | <0.001 | n.s. |
|
| 31% | 68% | 31% | 42% | <0.001 | n.s. |
|
| 81% | 62% | 19% | 58% | <0.001 | 3.33 |
|
| 5% | 2% | 56% | 0% | <0.001 | 0.07 |
|
| 11% | 2% | 0% | 0% | 0.007 | n.s. |
|
| 21% | 51% | 19% | 32% | 0.001 | n.s. |
Only virulence factors showing a P-value (from Chi-square test) <0.01 are shown (in alphabetic order). Percentages do not add up to 100% since fractions are per phylogroup.
Fig 4Boxplot of number of total number of virulence markers among seropathotypes according the classicial Karmali classification.
Solid horizontal line represents the median, the box represents the 25%-75% quartile range, the stems represent the minimum and maximum values, asterisks represent outliers.
Fig 5Boxplot of number of total number of virulence markers among seropathotypes according to the modified classification (modSPT).
Solid horizontal line represents the median, the box represents the 25%-75% quartile range, the stems represent the minimum and maximum values, asterisks represent outliers.
human
origin compared to isolates of non-human origin included ent/espL2, nleA, nleG9, efa1, adfO, and nleH1–2 (Table 4).Summary of associations of gene targets with different groupings of isolates based on the Pearson Chi-square value (χ2) and the odds ratio (OR).
| Target | HAS versus non-HAS | human versus non-human |
|
| ||||
|---|---|---|---|---|---|---|---|---|
| χ2
| OR (95% CI) | χ2
| OR (95% CI) | χ2
| OR (95% CI) | χ2
| OR (95% CI) | |
|
| 9.89 | 4.0 (1.6–10.0) | 9.04 | 3.6 (1.5–5.66) | ||||
|
| ||||||||
|
| 7.68 | 3.8 (1.4–10.5) | 7.16 | 3.2 (1.3–7.7) | ||||
|
| 16.38 | 0.12 | ||||||
|
| ||||||||
|
| ||||||||
|
| 8.76 | 0.17 (0.04–0.63) | 6.5 | 4.9 (1.3–18.6) | ||||
|
| 4.49 | 4.6 | 5.65 | 0.17 | ||||
|
| 8.60 | 9.0 | 47.96 | 72.0 (9.0–575.7) | ||||
|
| ||||||||
|
| 20.16 | 7.2 (2.8–18.7) | 3.89 | 2.5 (1.0–6.6) | 124.8 | 348 (43–2777) | ||
|
| ||||||||
|
| ||||||||
|
| 16.97 | 5.9 (2.4–14.8) | 8.60 | 3.7 (1.5–9.4) | 96.63 | 47 (18–125) | 6.39 | 0.15 |
|
| 31.57 | 11.3 (4.2–30.1) | 4.01 | 2.8 (1.0–7.7) | 108.4 | 252 (32–1987) | ||
|
| 14.78 | 11.0 (2.5–48.1) | ||||||
|
| 28.21 | 11.3 (4.0–32.4) | 4.47 | 3.6 (1.0–12.9) | 66.81 | 62 (13–285) | ||
|
| 30.6 | 35.8 |
| |||||
|
| 4.39 | 3.1 (1.0–9.6) | 6.79 | 0.45 (0.25–0.83) | 55.56 | 17.6 (7.2–42.8) | 3.92 | 1.9 (1.0–3.8) |
|
| 4.38 | 0.52 (0.26–1.05) | ||||||
|
| 13.00 | 5.8 (2.0–16.7) | 82.24 | 152 (19–1194) | ||||
|
| 9.96 | 4.6 (1.7–13.0) | 89.87 | 92 (20–425) | ||||
|
| 3.90 | 3.0 (1.0–9.0) | 98.64 | 187 |
| |||
|
| 30.6 | 36 |
| |||||
|
| 63.4 | 91 |
| |||||
|
| 17.83 | 6.4 (2.5–16.4) | 136.04 | 443 (55–3562) | ||||
|
| 3.89 | 2.5 (1.0–6.6) | 136.6 | 394 |
| |||
|
| 9.35 | 5.5 (1.7–18.1) | 52.69 | 81 (10–643) | ||||
|
| 6.47 | 3.4 (1.3–9.3) | 136.60 | 394 |
| |||
|
| 20.16 | 7.2 (2.8–18.7) | 136.6 | 394 |
| |||
|
| 31.96 | 12.2 (4.4–34.1) | 76.78 | 75 (16–347) | ||||
|
| 35.15 | 42 |
| |||||
|
| 3.89 | 3.4 (0.9–12.1) | 83.22 | 138 |
| |||
|
| 5.00 | 3.4 (1.1–10.6) | 88.30 | 152 |
| |||
|
| 4.47 | 3.6 (1.0–12.9) | 77.18 | 137 (17–1081) | ||||
|
| 5.82 | 0.17 | ||||||
|
| 29.87 | 0.03 (0.003–0.19) | ||||||
|
| 6.89 | 3.1 (1.3–7.6) | 19.25 | 4.7 (2.3–9.8) | ||||
|
| 12.92 | 9.6 (2.2–41.4) | 35.15 | 42.3 |
| |||
| TspE4.C2 | ||||||||
|
| 16.79 | 6.0 (2.4–15.5) | ||||||
|
| 7.71 | 0.13 (0.02–0.95) | ||||||
Empty cells mean no significant association.
a Chi-square value. Asterisks indicate the level of significance
*** is P<0.001
** is 0.001
* is 0.01
b Odds-ratio (OR) and 95% confidence interval (CI).
c One quadrant of the 2x2 contingency table contains a zero. For calculation of the odds-ratio the zero is replaced by 1. The given odds ratio value is the minimal value for that specific gene. No confidence interval is calculated.
d No statistics were calculated because variable (gene) is a constant (i.e. does not occur among eae-negative isolates).